Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Evotec : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto

share with twitter share with LinkedIn share with facebook
share via e-mail
09/21/2017 | 09:48pm CET

By a News Reporter-Staff News Editor at Drug Week -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation ("MI") announced the launch of "LAB150". This transformational Toronto-based partnership will give Canadian academic institutions and teaching hospitals access to the world-class infrastructure and drug discovery expertise of Evotec and pair it with cutting-edge drug discovery projects emerging from the 15 member institutions of MaRS Innovation (see also Evotec AG).

A crucial lack of the funding, specialised infrastructure and drug development expertise necessary to translate disease-related biological pathways into focused drug discovery programmes has been a persistent hindrance for promising biomedical research to reach clinical development and the marketplace in Canada and globally. LAB150 addresses precisely this challenge. The goal of this new partnership is to significantly shorten the drug discovery timeline and to generate viable start-up companies with high potential for success.

MI will identify projects and build technical and business cases from scientific concepts that focus on first-in-class and disease-related novel biological pathways. Evotec will contribute infrastructure and pre-clinical drug development expertise to translate such discoveries into potential medicines.

Dr Rafi Hofstein, President & CEO of MI, said: "LAB150 represents an extraordinary opportunity for Canada to bridge the drug discovery gap with the objective of stimulating the formation of new ventures in downtown Toronto and of developing ground-breaking therapies to benefit Canadians and others around the world." Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are delighted to expand our Academic BRIDGE network and partnerships together with MaRS Innovation. The dramatic reduction of search costs for capital for the first translational work packages of academic science, early validation of experiments, and industry-proven drug discovery processes will add a highly valuable new tool to the Canadian ecosystem of innovation."

Evotec is seeking partnerships across all biotechnology innovation hubs and has selected MI and Toronto as a top-notch venue for its first North American partnership. This is a testament not only to MI's novel approach to commercialisation but also to the quality of science and innovation of MI's member institutions. Supported by financial contributions from both MI and Evotec, this newly formed five-year partnership will accelerate the development and commercialisation of Canadian-born therapies delivered globally. MI and Evotec are already collaborating on other projects, notably Fibrocor Therapeutics LP, a company based in Toronto, which focuses on developing first-in-class therapeutics targeting fibrotic diseases.

The name of this partnership, LAB150, commemorates Canada's 150th anniversary.

Keywords for this news article include: Evotec AG.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EVOTEC AG
01:40p CORRECTION OF A RELEASE FROM 11.12.2 : 40 CET/CEST - Evotec AG: Release accordin..
12/11 EVOTEC : Academic Bridge LAB282 with Oxford University Celebrating One Year of I..
12/11 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
12/11 EVOTEC : S academic bridge lab282 with oxford university celebrating one year of..
12/04 EVOTEC : receives clinical milestone as part of its discovery alliance with Boeh..
12/01 EVOTEC : Receives clinical milestone as part of its discovery alliance with boeh..
12/01 EVOTEC : Receives clinical milestone as part of its discovery alliance with boeh..
11/30 EVOTEC AG : Release according to Article 26a of the WpHG [the German Securities ..
11/29 EVOTEC : Fibrocor Therapeutics Appoints Its First President & CEO
11/14 EVOTEC AG : announces first nine-month 2017 results and corporate update
More news
News from SeekingAlpha
11/17 Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare Conference - Slid..
11/11 Evotec's (EVOTF) CEO Werner Lanthaler on Q3 2017 Results - Earnings Call Tran..
11/08 MY JOURNEY TO FINANCIAL INDEPENDENCE : 85-Stock October Portfolio Update - Buyin..
11/08 Evotec AG ADR 2017 Q3 - Results - Earnings Call Slides
11/08 Evotec AG reports Q3 results
Financials (€)
Sales 2017 246 M
EBIT 2017 46,2 M
Net income 2017 28,9 M
Debt 2017 103 M
Yield 2017 -
P/E ratio 2017 71,75
P/E ratio 2018 49,25
EV / Sales 2017 9,15x
EV / Sales 2018 6,82x
Capitalization 2 143 M
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,5 €
Spread / Average Target 21%
EPS Revisions
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG74.01%2 524
CELLTRION, INC.--.--%23 085
LONZA GROUP57.44%19 299